Company

Location

Amt. (M)

Details

Date

TOTAL: $926.76M

Afferent Pharmaceuticals Inc.

San Mateo, Calif.

$55

Afferent raised $55M in a series C round led by Fidelity Management & Research Co., with participation from Jennison Associates LLC (on behalf of certain clients), New Leaf Ventures, Partner Fund Management, Redmile Group, Tekla Healthcare Investors, and Tekla Life Science Investors, along with what the company described as a blue-chip public investment fund

7/10/15

Anaptysbio Inc.

San Diego

$40

Raised $40M in a series D round from BVF Partners L.P. and its affiliates, Biomed Ventures, Cormorant Asset Management, Frazier Healthcare, HBM Healthcare Investments, Longwood Capital Partners, Novo A/S and additional undisclosed investors

7/16/15

Aspyrian Therapeutics Inc.

San Diego

$4.25

Aspyrian raised $4.25M as part of a series A extension financing

7/29/15

Autifony Therapeutics Ltd.

London

$12.5

Autifony raised £8M (US$12.5M) as an extension to its series A; the firm raised £10M when it was spun out of Glaxosmithkline plc in August 2011, with a £5.5M first extension in June 2013

7/20/15

Cevec Pharmaceuticals GmbH

Cologne, Germany

$5

Cevec completed a financing round of €4.5M (US$4.9M)

7/23/15

Dauntless Pharmaceuticals Inc.

San Diego

$12

Dauntless raised $12M in a series A round from Sofinnova Ventures

7/22/15

Entasis Therapeutics Inc.

Waltham, Mass.

$40

Astrazeneca plc spun out Entasis, fully funding a $40M series A, which closed in March

7/20/15

Gensight Biologics SA

Paris

$36

Gensight raised $36M in a series B preferred stock financing from Fidelity Management & Research Co., Jennison Associates, Sphera Global Healthcare Fund, Perceptive Advisors and Healthcap, as well as existing series A investors; Leerink Partners LLC acted as the exclusive placement agent

7/24/15

Histogen Inc.

San Diego

$18

Histogen entered a deal for Wealthforge to serve as lead placement agent in collaboration with Gar Wood Securities in the firm's $18M series D round

7/15/15

Immunocore Ltd.

Oxford, UK

$320

Raised $320M in private financing from new investors Woodford Investment Management, Malin Corp. plc and Eli Lilly and Co., along with other new and existing investors, such as Fidelity Management & Research Co.

7/17/15

Innavirvax SA

Evry, France

$4

Innavirvax completed its third funding round for €3.6M (US$4M)

7/10/15

Kalvista Pharmaceuticals Ltd.

Boston and Salisbury, UK

$33

Kalvista raised $33M in a series B round with European backers Novo A/S and SV Life Sciences, as well as U.S. investors RA Capital Management, Longwood Fund and Venrock

7/23/15

Leon Nanodrugs GmbH

Munich

$20.55

Leon Nanodrugs completed the first closing of its series A preferred stock offering at €18.5M (US$20.55M) led by TVM Capital Life Science, based in Munich and Montreal, with participation from Signet Healthcare Partners (USA), Lifecare Partners (Switzerland), CD-Venture (Germany), Albany Private Equity Holding (Australia), and a non-disclosed Family Office from Germany

7/28/15

Mereo Biopharma Ltd.

London

$119

Mereo raised $119M in a series A round from Woodford Investment Management and Invesco Perpetual

7/30/15

Oncobiologics Inc.

Cranbury, N.J.

$31

Oncobiologics raised $31M in a round led by Perceptive Advisors, and including Cormorant Global Healthcare Master Fund, Longwood Capital Partners and Venbio Select Fund, as well as Proximare Lifesciences Fund, OSSB Pharma Fund and MIH Fund

7/28/15

Protagonist Therapeutics Inc.

Milpitas, Calif.

$40

Raised $40M in an oversubscribed series C financing led by Canaan Partners, with participation from Adage Capital Management, RA Capital Management and Foresite Capital, as well as existing investors including Johnson & Johnson Innovation, JJDC, Lilly Ventures, Pharmstandard International S.A. and Starfish Ventures

7/16/15

Ra Pharmaceuticals Inc.

Cambridge, Mass.

$59

Ra completed a $58.5M series B financing co-led by RA Capital Management, Novo Ventures and Lightstone Ventures, and joined by new investors Rock Springs Capital and Limulus Venture Partners; it also included existing investors, New Enterprise Associates, Novartis Venture Fund, Morgenthaler Ventures and Amgen Ventures

7/24/15

Rana Therapeutics Inc.

Cambridge, Mass.

$55

Rana raised $55M in a series B round from Atlas Venture, Monsanto Co., Partners Innovation Fund, MRL Ventures, the Baupost Group LLC, Rock Springs Capital Management, Brookside Capital, Leerink Partners LLC and an undisclosed blue chip public investment fund, and existing investors MS Ventures, Omega Funds, Pfizer Venture Investments and SR One

7/23/15

Siteone Therapeutics Inc.

Bozeman, Mont.

ND

Completed an investment by Next Frontier Capital and 2M Cos. Inc., plus current investors, including Sears Capital Management, Biobrit LLC, Mission Bay Capital and Z Investments

7/16/15

Sutrovax Inc. (spinout of Sutro Biopharma Inc.)

South San Francisco

$22

Sutrovax raised $22M in a series A round led by Abingworth, with participation from Longitude Capital, Roche Venture Fund and CTI Life Sciences Fund

7/24/15

TC Biopharm Ltd.

Edinburgh, Scotland

$1

Investing Women led the £680,000 ($1.063M) investment, with support from Scottish Investment Bank and WH Partnership

7/14/15

Notes

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

This chart includes only biotech companies that develop therapeutics.

ND = Not disclosed.